Paratek Pharmaceuticals (FRA:N4CN) FCF Margin % : -4.67% (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Paratek Pharmaceuticals's Free Cash Flow for the three months ended in Jun. 2023 was €-1.6 Mil. Paratek Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was €35.1 Mil. Therefore, Paratek Pharmaceuticals's FCF Margin % for the quarter that ended in Jun. 2023 was -4.67%.

As of today, Paratek Pharmaceuticals's current FCF Yield % is -19.03%.

The historical rank and industry rank for Paratek Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:N4CN' s FCF Margin % Range Over the Past 10 Years
Min: -332811.11 Med: -474.6 Max: -14.36
Current: -14.36

During the past 13 years, the highest FCF Margin % of Paratek Pharmaceuticals was -14.36%. The lowest was -332811.11%. And the median was -474.60%.

FRA:N4CN's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -139.09 vs FRA:N4CN: -14.36

Paratek Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Paratek Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals FCF Margin % Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-474.60

-811.66

-238.53

-40.22

-43.89

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
FCF Margin %	Get a 7-Day Free Trial															-52.62	-44.60	-27.69	37.86	-4.67

Competitive Comparison of Paratek Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Paratek Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paratek Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's FCF Margin % falls into.

Paratek Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Paratek Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-62.471	/	142.344
	=	-43.89 %

Paratek Pharmaceuticals's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1.639	/	35.131
	=	-4.67 %

Paratek Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines